ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1216

The Relationship Between Serum Homocysteine, Uric Acid and Renal Function in Chronic Gouty Patients: 2 Year Follow-up Results

Eun-Hye Park1, Sang Tae Choi2 and Jung-Soo Song1, 1Chung-Ang University College of Medicine, Seoul, South Korea, 2Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Kidney and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Hyperhomocysteinemia is one of the important factors for the endothelial cell damage and also a risk factor for cardiovascular events. Gout is known to be associated with cardiovascular disease (CVD) as well. Although both hyperhomocysteinemia and gout are related to CVD, the only few cases about serum homocysteine (Hcy) in gouty patients have been reported. In this study, we investigated the associations between serum Hcy level and the other parameters including serum uric acid level, renal function, and cholesterol profiles in chronic gouty patients with longitudinal follow-up data.

Methods: Ninety-one male patients with chronic gout and 97 age-matched healthy male controls were included in this study, and the average age of each was 51.19 ± 15.08 and 51.57 ± 17.01 years old, respectively. Among them, 33 patients with gout and 39 healthy controls underwent follow-up tests for Hcy levels with 24.00 ± 9.12 months on average. Serum Hcy levels were measured by a competitive immunoassay using direct chemiluminescent. The estimated glomurular filtration rate (eGFR) was calculated using modification of diet in renal disease equation, and then chronic kidney disease (CKD) was defined as an eGFR below 60 ml/min/1.73m2.

Results: In the serum uric acid level, there was no significant difference between chronic gouty patients and controls (6.15 ± 2.23 mg/dL vs 5.82 ± 1.22 mg/dL, p = 0.214). In contrast, gouty patients showed significantly higher levels in serum Hcy than those in controls (13.96 ± 4.05 μmol/L vs 12.67 ± 3.51 μmol/L, p = 0.022). In patients with chronic gout, serum Hcy level was negatively correlated with eGFR (γ= -0.413, p < 0.001), while it was uncorrelated with serum uric acid levels or cholesterol profiles. Serum Hcy levels were not different between the groups treated with allopurinol and with benzbromarone. When we observed the follow-up results in chronic gouty group, the change of serum Hcy level was positively correlated with the change of serum creatinine level (γ = 0.560, p < 0.001), and negatively correlated with the change of eGFR (γ = -0.556, p < 0.001). However the change of serum Hcy level was uncorrelated with the changes of uric acid level or the lipid profiles. The chronic gouty patients with CKD showed significantly higher serum Hcy level than those without CKD (17.45 ± 4.68 μmol/L vs 13.15 ± 3.46 μmol/L, p < 0.001), and the follow-up result also showed similar tendency (19.12 ± 4.29 μmol/L vs 15.69 ± 5.73 μmol/L, p = 0.059). In multiple linear analyses, serum Hcy level was affected by eGFR (β = -0.385, p< 0.001), however, was not affected by the serum uric acid level.

Conclusion: Serum Hcy level was elevated in chronic gouty patients than in controls. The change of serum Hcy level was negatively correlated with the change of eGFR. Hyperhomocysteinemia in chronic gouty patients was related with decreased renal function, and was not with serum uric acid or lipid profiles.


Disclosure:

E. H. Park,
None;

S. T. Choi,
None;

J. S. Song,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-serum-homocysteine-uric-acid-and-renal-function-in-chronic-gouty-patients-2-year-follow-up-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology